Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel.

Self-assembled nanoparticles based on hydrophobically modified glycol chitosan (HGC) were prepared as a carrier for paclitaxel. HGC conjugates were prepared by chemically linking 5beta-cholanic acid to glycol chitosan chains using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide chemistry. In phosphate-buffered saline (PBS; pH 7.4), the synthesized HGC conjugates formed nano-sized particles with a diameter of 200 nm and exhibited high thermodynamic stability as reflected by their low critical aggregation concentration (0.03 mg/ml). Paclitaxel was efficiently loaded into HGC nanoparticles up to 10 wt.% using a dialysis method. The paclitaxel-loaded HGC (PTX-HGC) nanoparticles were 400 nm in diameter and were stable in PBS for 10 days. These PTX-HGC nanoparticles also showed sustained release of the incorporated of paclitaxel (80% of the loaded dose was released in 8 days at 37 degrees C in PBS). Owing to sustained release, the PTX-HGC nanoparticles were less cytotoxic to B16F10 melanoma cells than free paclitaxel formulated in Cremophor EL. Injection of PTX-HGC nanoparticles into the tail vein of tumor-bearing mice prevented increases in tumor volume for 8 days. Finally, PTX was less toxic to the tumor-bearing mice when formulated in HGC nanoparticles than when formulated with Cremophor EL.

[1]  D. Faulds,et al.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. , 1994, Drugs.

[2]  S. Arbuck,et al.  Taxol: the first of the taxanes, an important new class of antitumor agents. , 1992, Seminars in oncology.

[3]  I. Rubinstein,et al.  Sterically Stabilized Phospholipid Mixed Micelles: In Vitro Evaluation as a Novel Carrier for Water-Insoluble Drugs , 2003, Pharmaceutical Research.

[4]  G. Kwon,et al.  Polymeric micelles for delivery of poorly water-soluble compounds. , 2003, Critical reviews in therapeutic drug carrier systems.

[5]  G. Wess,et al.  Bile acids in drug discovery , 1998 .

[6]  D. Kingston,et al.  The chemistry of taxol. , 1991, Pharmacology & therapeutics.

[7]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[8]  H. S. Oh,et al.  In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[9]  T. Okano,et al.  Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. , 1990, Cancer research.

[10]  P. Carlile,et al.  Thermodilution measurement of lung water. , 1985, Clinics in chest medicine.

[11]  Teruo Okano,et al.  Physical Entrapment of Adriamycin in AB Block Copolymer Micelles , 1995, Pharmaceutical Research.

[12]  V. Martin Overview of paclitaxel (TAXOL). , 1993, Seminars in oncology nursing.

[13]  M. Green,et al.  Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Gregory Re,et al.  Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. , 1993 .

[15]  Hyun Joon Shin,et al.  Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[16]  I. Kwon,et al.  Synthesis and characterization of sugar-bearing chitosan derivatives: aqueous solubility and biodegradability. , 2003, Biomacromolecules.

[17]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[18]  M. Alonso,et al.  The potential of chitosan in ocular drug delivery , 2003, The Journal of pharmacy and pharmacology.

[19]  R. Kaushik,et al.  Chitosan microspheres as a potential carrier for drugs. , 2004, International journal of pharmaceutics.

[20]  Kwangmeyung Kim,et al.  Physicochemical characterizations of self-assembled nanoparticles of glycol chitosan-deoxycholic acid conjugates. , 2005, Biomacromolecules.

[21]  J. Burroughs,et al.  Overview of Taxol safety. , 1993, Journal of the National Cancer Institute. Monographs.

[22]  Ick Chan Kwon,et al.  Physicochemical Characteristics of Self-Assembled Nanoparticles Based on Glycol Chitosan Bearing 5β-Cholanic Acid , 2003 .

[23]  I. Kwon,et al.  Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(ε-caprolactone) copolymer as a carrier for paclitaxel , 2003 .

[24]  Tae Gwan Park,et al.  Folate receptor targeted biodegradable polymeric doxorubicin micelles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[25]  J. Thigpen,et al.  Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Nguyen-Huu,et al.  Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[27]  R. Dorr Pharmacology and Toxicology of Cremophor EL Diluent , 1994, The Annals of pharmacotherapy.

[28]  R. Duncan The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.